Pulmonary Function Test Part 1 PptDr Mona Allangawi

Embed Size (px)

Citation preview

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    1/84

    PFT IPFT I 11

    Pulmonary function testPulmonary function testPart IPart I

    Dr.Mona AllangawiDr.Mona Allangawi

    ConsultantConsultant Pulmonary/AllergyPulmonary/Allergy

    Hamad General HospitalHamad General Hospital -- HMCHMC

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    2/84

    PFT IPFT I 22

    Pulmonary function test :Pulmonary function test :Group of procedures that measure the function of theGroup of procedures that measure the function of the

    lungslungs

    1.1. SpirometrySpirometry

    2.2. Lung volumesLung volumes

    3.3. Gas transferGas transfer

    4.4. Bronchial chalengeBronchial chalenge

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    3/84

    PFT IPFT I 33

    IndicationsIndications

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    4/84

    PFT IPFT I 44

    A.DiagnosticA.Diagnostic

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    5/84

    PFT IPFT I 55

    Symptoms:Symptoms:dyspnea, wheezing, orthopnea, cough,dyspnea, wheezing, orthopnea, cough,phlegm production, chest painphlegm production, chest pain

    Signs:Signs:

    decreased breath sounds, overinflation,decreased breath sounds, overinflation,expiratory slowing, cyanosis, chest deformitory,expiratory slowing, cyanosis, chest deformitory,unexplained cracklesunexplained crackles

    Abnormal laboratory tests:Abnormal laboratory tests:

    hypoxemia, hypercapnia, polycythemia,hypoxemia, hypercapnia, polycythemia,abnormal chest radiographsabnormal chest radiographs

    To measure the effect of disease on pulmonaryTo measure the effect of disease on pulmonaryfunctionfunction

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    6/84

    PFT IPFT I 66

    To screen individuals at risk of having pulmonaryTo screen individuals at risk of having pulmonarydiseasesdiseases

    1.1. SmokersSmokers

    2.2. Individuals in occupations with exposures toIndividuals in occupations with exposures toinjurious substancesinjurious substances

    To assess preoperative riskTo assess preoperative risk

    To assess prognosis (lung transplant, etc.)To assess prognosis (lung transplant, etc.)

    To assess health status before enrollment inTo assess health status before enrollment instrenuous physical activity programsstrenuous physical activity programs

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    7/84

    PFT IPFT I 77

    B. MonitoringB. Monitoring

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    8/84

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    9/84

    PFT IPFT I 99

    C. Disability/Impairment EvaluationsC. Disability/Impairment Evaluations

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    10/84

    PFT IPFT I 1010

    To assess patients as part of a rehabilitationTo assess patients as part of a rehabilitationprogramprogram

    MedicalMedical

    IndustrialIndustrial

    VocationalVocational

    To assess risks as part of an insuranceTo assess risks as part of an insurance

    evaluationevaluation

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    11/84

    PFT IPFT I 1111

    ContraindicationsContraindications

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    12/84

    PFT IPFT I 1212

    Hemoptysis of unknown originHemoptysis of unknown origin PneumothoraxPneumothorax

    Unstable angina pectorisUnstable angina pectoris

    Recent myocardial infarctionRecent myocardial infarction

    Thoracic aneurysms

    Thoracic aneurysms

    Abdominal aneurysmsAbdominal aneurysms

    Cerebral aneurysmsCerebral aneurysms

    Recent eye surgery (increased intraocular pressureRecent eye surgery (increased intraocular pressureduring forced expiration)during forced expiration)

    Recent abdominal or thoracic surgical proceduresRecent abdominal or thoracic surgical procedures

    History of syncope associated with forced exhalationHistory of syncope associated with forced exhalation

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    13/84

    PFT IPFT I 1313

    Pulmonary function test:Pulmonary function test:

    1.1. SpirometrySpirometry

    2.2. Lung volumesLung volumes

    3.3. Gas transferGas transfer4.4. Bronchial chalengeBronchial chalenge

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    14/84

    PFT IPFT I 1414

    What is a spirometry ??What is a spirometry ??SpirometrySpirometry isis aa measuremeasure ofof airflowairflow andand

    lunglung volumesvolumes duringduring aa forcedforced expiratoryexpiratory

    maneuvermaneuver fromfrom fullfull inspirationinspiration

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    15/84

    PFT IPFT I 1515

    How to do it ??How to do it ??

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    16/84

    PFT IPFT I 1616

    1.1. Stand or sit up straight (The patient places aStand or sit up straight (The patient places aclip over the nose )clip over the nose )

    2.2. Inhale maximallyInhale maximally

    3.3. Get a good seal around mouthpiece of theGet a good seal around mouthpiece of thespirometerspirometer

    4.4. Blow out as hard as fast as possible andBlow out as hard as fast as possible andcount for at least 6 seconds.count for at least 6 seconds.

    5.5. Record the best of three trialRecord the best of three trial

    *pt should hold bronchodilator few hrs before the test*pt should hold bronchodilator few hrs before the test

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    17/84

    PFT IPFT I 1717

    1. Volume Time Graph 2. Flow1. Volume Time Graph 2. Flow--volume loopsvolume loops

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    18/84

    PFT IPFT I 1818

    Volume Time GraphVolume Time Graph

    The volume is plotted against the time, it displays

    The volume is plotted against the time, it displaysthe expiration.the expiration.

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    19/84

    PFT IPFT I 1919

    1.1. FVCFVC2.2. FEVFEV11

    3.3. FEVFEV11/FVC/FVC

    4.4. FEFFEF2525%%

    5.5. FEFFEF7575%%

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    20/84

    PFT IPFT I 2020

    Forced Vital Capacity (FVC)Forced Vital Capacity (FVC)The total amount of air expired asThe total amount of air expired asquickly as possible after taking thequickly as possible after taking the

    deepest possible breath.deepest possible breath.

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    21/84

    PFT IPFT I 2121

    FEV1FEV1 ::

    Volume of air which can be forciblyVolume of air which can be forciblyexhaled from the lungs in the firstexhaled from the lungs in the first

    second of a forced expiratorysecond of a forced expiratorymaneuver.maneuver.

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    22/84

    PFT IPFT I 2222

    FEVFEV11/FVC/FVC

    Ratio ofRatio ofFEVFEV11 toto FVCFVC::

    It indicates what percentage of the totalIt indicates what percentage of the total FVCFVCwas expelled from the lungs during the firstwas expelled from the lungs during the first

    second of forced exhalationsecond of forced exhalationThis value is critically important in theThis value is critically important in thediagnosis of obstructive and restrictivediagnosis of obstructive and restrictive

    diseasesdiseases

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    23/84

    PFT IPFT I 2323

    FEF25%Amount of air that was forcibly expelled in the firstAmount of air that was forcibly expelled in the first

    25% of the total forced vital capacity test.25% of the total forced vital capacity test.

    FEF75%FEF75%

    The amount of air expelled from the lungs during theThe amount of air expelled from the lungs during the

    first (75%) of the forced vital capacity test.first (75%) of the forced vital capacity test.

    FEF25%FEF25%--75%75%

    The amount of air expelled from the lungs duringThe amount of air expelled from the lungs duringthe middle half of the forced vital capacity test.the middle half of the forced vital capacity test.

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    24/84

    PFT IPFT I 2424

    FlowFlow--volume loopsvolume loops

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    25/84

    PFT IPFT I 2525

    FlowFlow--volume loopsvolume loops

    Is a plot of inspiratoryIs a plot of inspiratoryand expiratory flow inand expiratory flow in

    the vertical axis againstthe vertical axis againstvolume in the horizentalvolume in the horizentalaxis, during theaxis, during theperformance ofperformance of

    maximally forcedmaximally forcedinspiratory andinspiratory andexpiratory maneuvers.expiratory maneuvers.

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    26/84

    PFT IPFT I 2626

    The contour of the loop assists in theThe contour of the loop assists in thediagnosis and localization of airwaydiagnosis and localization of airwayobstruction as different lung disordersobstruction as different lung disordersproduce distinct ,easily recognizedproduce distinct ,easily recognizedpattern.pattern.

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    27/84

    PFT IPFT I 2727

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    28/84

    PFT IPFT I 2828

    Useful also in assesing acceptability of the manoeuvers:Useful also in assesing acceptability of the manoeuvers:11.. Lack of early peak suggest poor effort.Lack of early peak suggest poor effort.22.. Sudden tailing off of expiration curve suggest that theSudden tailing off of expiration curve suggest that the

    patient stopped blowing too earlypatient stopped blowing too early

    33.. CoughCough

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    29/84

    PFT IPFT I 2929

    Obstructive V/S restrictive lungObstructive V/S restrictive lungdisease ???disease ???

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    30/84

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    31/84

    PFT IPFT I 3131

    Common Obstructive Lung DiseasesCommon Obstructive Lung DiseasesAsthmaAsthma

    COPDCOPD (chronic bronchitis, emphysema and(chronic bronchitis, emphysema and

    the overlap between them).the overlap between them). Cystic fibrosis.Cystic fibrosis.

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    32/84

    PFT IPFT I 3232

    --Airflow is reduced because the airways narrow and theAirflow is reduced because the airways narrow and the FEVFEV11 isis

    reducedreduced--Spirogram may continue to rise for more thanSpirogram may continue to rise for more than 66 seconds because lungseconds because lungtake longer to emptytake longer to empty--FVCFVC may also be reduced because gas is trapped behind obstructedmay also be reduced because gas is trapped behind obstructedbronchi due to increase in intrathoracic pressure during maneuverbronchi due to increase in intrathoracic pressure during maneuvercompresses airways causing early airway closure and gas trapping butcompresses airways causing early airway closure and gas trapping but

    this reduction to a lesser extent thanthis reduction to a lesser extent than FEVFEV11

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    33/84

    PFT IPFT I 3333

    FEV1FEV1 80% 80% of predictedof predicted NormalNormalFEV1FEV1 6060--80%80% of predictedof predicted mild obst.mild obst.

    FEV1FEV1 4040--60%60% of predictedof predicted moderatemoderate

    FEV1 FEV1 40%40% of predictedof predicted severesevere

    The cardinal feature isThe cardinal feature is FEV1/FVCFEV1/FVC ratio Ifratio If

    the ratio less thanthe ratio less than 7070 consider obstructedconsider obstructed

    disease .disease .*Predictors: Sex, Age, Ht*Predictors: Sex, Age, Ht

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    34/84

    PFT IPFT I 3434

    Predictors: Sex, Age, Ht ??Predictors: Sex, Age, Ht ??

    The measurements are related to the following factors:The measurements are related to the following factors:

    AgeAge ::FVC and flow rates decline with age. The value of FVC increases up toFVC and flow rates decline with age. The value of FVC increases up to24 years of age and remain stable to age 35.24 years of age and remain stable to age 35.

    HeightHeight ::

    All spirometric measurements increase with body weight. It is due to anAll spirometric measurements increase with body weight. It is due to anincrease in number and/or size of alveoli relative to airways, the largerincrease in number and/or size of alveoli relative to airways, the largerlungs are likely to take longer than smaller one.lungs are likely to take longer than smaller one.

    SexSex ::Most pulmonary function values are lower in female than maleMost pulmonary function values are lower in female than male..

    WeightWeight ::A spirometric results are positively correlated with weight to the extentA spirometric results are positively correlated with weight to the extent

    that increased weight means growth or muscle mass. Beyond this (inthat increased weight means growth or muscle mass. Beyond this (inobesity) spirometric values (and lung values specially ERV) decreaseobesity) spirometric values (and lung values specially ERV) decreasewith greater weight.with greater weight.

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    35/84

    PFT IPFT I 3535

    Flow volume loop inFlow volume loop in

    Obstructive lung diseaseObstructive lung disease

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    36/84

    PFT IPFT I 3636

    AsthmaAsthma

    PeakPeak expiratoryexpiratory flowflow reducedreducedsoso maximummaximum heightheight ofof thethe looploopisis reducedreduced

    AirflowAirflow reducesreduces rapidlyrapidly withwiththethe reductionreduction inin thethe lunglungvolumesvolumes becausebecause thethe airwaysairwaysnarrownarrow andand thethe looploop becomebecomeconcaveconcave

    ConcavityConcavity maymay bebe thethe indicatorindicatorofof airflowairflow obstructionobstruction andand maymaypresentpresent beforebefore thethe changechange ininFEVFEV11 oror FEVFEV11/FVC/FVC

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    37/84

    PFT IPFT I 3737

    EmphysemaEmphysema

    AirwaysAirways maymay collapsecollapse duringduringforcedforced expirationexpiration becausebecause ofofdestructiondestruction ofof thethe supportingsupportinglunglung tissuetissue causingcausing veryveryreducedreduced flowflow at at lowlow lunglungvolumevolume andand aa characteristiccharacteristic(dog(dog--leg)leg) appearanceappearance toto thethe

    flowflow volumevolume curvecurve

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    38/84

    PFT IPFT I 3838

    ReversibilityReversibility

    Improvement inImprovement in FEV1 by 12FEV1 by 12--15% or 200 ml15% or 200 ml in repeatingin repeatingspirometry after treatment withspirometry after treatment withSulbutamol 2.5mg or ipratrobiumSulbutamol 2.5mg or ipratrobiumpromide by nebuliser afterpromide by nebuliser after 1515--3030minutesminutes

    Reversibility is a characteresticReversibility is a characteresticfeature of B.Asthmafeature of B.Asthma

    In chronic asthma there may beIn chronic asthma there may beonly partial reversibility of theonly partial reversibility of the

    airflow obstructionairflow obstruction While in COPD the airflow isWhile in COPD the airflow is

    irriversible although some casesirriversible although some casesshowed significant improvement.showed significant improvement.

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    39/84

    PFT IPFT I 3939

    Interpretation of PFT

    sInterpretation of PFT

    sStepStep 11.. LookLook at at thethe FlowFlow--VolumeVolume looploop toto determinedetermine

    acceptabilityacceptability ofof thethe test,test, andand looklook forfor upperupper airwayairway

    obstructionobstruction patternpattern..

    StepStep 22.. LookLook atat thethe FEVFEV11 toto determinedetermine ifif it it isis normalnormal ((

    8080%% predicted)predicted)..

    StepStep 33.. LookLook atatFVCFVC toto determinedetermine ifif it it isis withinwithin normalnormal

    limitslimits (( 8080%%))..

    StepStep 44.. LookLook atat thethe FEVFEV11/FVC/FVC ratioratio toto determinedetermine ifif it it isis

    withinwithin normalnormal limitslimits (( 7070%%))..

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    40/84

    PFT IPFT I 4040

    StepStep 55.. LookLook atatFEFFEF2525--7575%% (Normal(Normal (( 6060%%))

    IfIf FEVFEV11,, FEVFEV11/FVC/FVC ratio,ratio, andand FEFFEF2525--7575%% allall areare

    normal,normal, thethe patientpatient hashas aa normalnormal PFTPFT..

    IfIf bothboth FEVFEV11 andand FEVFEV11/FVC/FVC areare normal,normal, butbut FEFFEF2525--

    7575%% isis 6060%% ,then,then thinkthink aboutabout earlyearly obstructionobstruction oror

    smallsmall airwaysairways obstructionobstruction..

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    41/84

    PFT IPFT I 4141

    IfIf FEVFEV11 8080%% andand FEVFEV11/FVC/FVC 7070%%,, therethere isis

    obstructiveobstructive defect,defect, if if FVCFVC isis normal,normal, it it isis purepure

    obstructionobstruction.. IfIf FVCFVC 8080%% ,, possibilitypossibility ofof additionaladditional

    restrictionrestriction isis therethere..

    IfIfFEVFEV11 8080%% ,, FVCFVC 8080%% andand FEVFEV11/FVC/FVC 7070%% ,,

    therethere isis restrictiverestrictive defect,defect, getget lunglung volumesvolumes toto confirmconfirm..

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    42/84

    PFT IPFT I 4242

    ExamplesExamples

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    43/84

    PFT IPFT I 4343

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    44/84

    PFT IPFT I 4444

    Mild Obstructive Defect with good response toMild Obstructive Defect with good response to

    bronchodilatorbronchodilator

    Diagnosis:Diagnosis:B.AsthmaB.Asthma

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    45/84

    PFT IPFT I 4545

    AA 6666 year old female complains ofyear old female complains of

    cough after dust exposurecough after dust exposure

    %Pred%PredRefRefMeasMeas

    858522..585822..22FVCFVC

    979711..858511..7979FEVFEV11

    72728181FEVFEV11/FVC/FVC

    828222..232311..8282FEFFEF 2525--7575

    10910955..2255..6767PEFPEF

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    46/84

    PFT IPFT I 4646

    Normal SpirometryNormal Spirometry

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    47/84

    PFT IPFT I 4747

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    48/84

    PFT IPFT I 4848

    Flow volume loop suggestive of obstructive diseaseFlow volume loop suggestive of obstructive disease

    Spirometry showed Severe Obstructive defect with noSpirometry showed Severe Obstructive defect with no

    response to bronchodilatorresponse to bronchodilator

    Increased FVC could be because of Airtrapping orIncreased FVC could be because of Airtrapping or

    could be combined obstructive and restrictive defect tocould be combined obstructive and restrictive defect to

    confirm need to do Lung Volumeconfirm need to do Lung Volume

    diagnosis :diagnosis :COPDCOPD

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    49/84

    PFT IPFT I 4949

    AA 7575 year old female has a history ofyear old female has a history of

    dyspnea and palpitationsdyspnea and palpitations

    %Pred%PredRefRefMeasMeas

    939322..828222..6262FVCFVC

    727211..989811..4545FEVFEV11

    69695555FEVFEV11/FVC/FVC

    202022..202000..4343FEFFEF2525--7575

    828255..484844..5050PEFPEF

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    50/84

    PFT IPFT I 5050

    MildObstructive defectMildObstructive defect

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    51/84

    PFT IPFT I 5151

    Large Airway ObstructionLarge Airway Obstruction

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    52/84

    PFT IPFT I 5252

    11.. Fixed obstructionFixed obstruction22..Variable extrathoracicVariable extrathoracic obstructionobstruction

    33..Variable intrathoracic obstructionVariable intrathoracic obstruction

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    53/84

    PFT IPFT I 5353

    Flow Volume Loop inFlow Volume Loop in

    Large Airway ObstructionLarge Airway Obstruction

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    54/84

    PFT IPFT I 5454

    Fixed obstructionFixed obstruction1. Post intubation stenosis1. Post intubation stenosis

    2. Goiter2. Goiter

    3. Endotracheal neoplasms3. Endotracheal neoplasms

    4. Bronchial stenosis4. Bronchial stenosis

    Maximum airflow isMaximum airflow islimited to a similar extentlimited to a similar extent

    in bothin both inspinspiration andiration andexpexpirationiration

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    55/84

    PFT IPFT I 5555

    VariableVariable extrextrathoracicathoracic

    ObstructionObstruction1. Bilateral and unilateral vocal cord1. Bilateral and unilateral vocal cord

    paralysisparalysis

    2. Vocal cord constriction2. Vocal cord constriction

    3. Reduced pharyngeal cross3. Reduced pharyngeal cross--

    sectional areasectional area4. Airway burns4. Airway burns

    The obstruction worsens inThe obstruction worsens ininspinspiration because theiration because the

    negative pressure narrowsnegative pressure narrowsthe trachea and inspiratorythe trachea and inspiratoryflow is reduced to a greaterflow is reduced to a greaterextent than expiratory flowextent than expiratory flow

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    56/84

    PFT IPFT I 5656

    In variableIn variable intrintrathoracicathoracicobstructionobstruction

    1.1. TracheomalaciaTracheomalacia2. Polychondritis2. Polychondritis

    3. Tumors of the lower trachea3. Tumors of the lower trachea

    or main bronchus.or main bronchus.The narrowing is maximal inThe narrowing is maximal inexpexpiration because ofiration because ofincreased intrathoracicincreased intrathoracicpressure compressing thepressure compressing the

    airway.airway.The flow volume loop shows aThe flow volume loop shows agreater reduction in thegreater reduction in the

    expiratoryexpiratory phasephase

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    57/84

    PFT IPFT I 5757

    Small Airways obstructionSmall Airways obstruction

    DiseasesDiseases affectingaffecting primarilyprimarily thethe smallsmall (peripheral)(peripheral)airwaysairways cancan bebe extensiveextensive yetyet notnot affectaffect thethe FEVFEV11(e(e..gg..earlyearly COPD,COPD, interstitialinterstitial granulomatousgranulomatous disorders)disorders)..

    SmallSmall airwaysairways statusstatus isis reflectedreflected byby thethe FEFFEF2525--7575%%(mid(mid--rangerange flow),flow), bestbest determineddetermined fromfrom thethe flowflow--volumevolume looploop..

    SomeSome patientspatients havehave normalnormal spirometryspirometry withwith thetheexceptionexception ofof aa reducedreduced FEFFEF2525--7575%%,, thisthis isis suggestivesuggestiveofof possiblepossible smallsmall airwaysairways dysfunctiondysfunction andand potentiallypotentiallyearlyearly obstructionobstruction..

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    58/84

    PFT IPFT I 5858

    ExampleExample

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    59/84

    PFT IPFT I 5959

    AA 3838 year old female complains ofyear old female complains of

    wheezing on exertionwheezing on exertion

    %Pr%Preedd

    RefRefMeasMeas

    10310333..545433..6666FVCFVC

    838322..777722..3030FEVFEV11

    78786363FEVFEV11/FVC/FVC

    515144..202022..1515FEFFEF2525--7575

    383866..252522..3939PEFPEF

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    60/84

    PFT IPFT I 6060

    Flow volume loop suggests a fixed upperFlow volume loop suggests a fixed upperairway obstructionairway obstruction

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    61/84

    PFT IPFT I 6161

    Effect of Smoking:Effect of Smoking: Smoking in patients with COPD is associatedSmoking in patients with COPD is associated

    with decline inwith decline in FEV1 of90FEV1 of90--150 mL/year150 mL/year

    Smoking cessation is (associated withSmoking cessation is (associated withincrease inincrease in FEV1FEV1 for first year) followed withfor first year) followed witha decline of only 30 mL/yeara decline of only 30 mL/year

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    62/84

    PFT IPFT I 6262

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    63/84

    PFT IPFT I 6363

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    64/84

    PFT IPFT I 6464

    Restrictive Lung DiseasesR

    estrictive Lung Diseases

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    65/84

    PFT IPFT I 6565

    A. Intrinsic Restrictive Lung DisordersA. Intrinsic Restrictive Lung Disorders

    1.1. SarcoidosisSarcoidosis

    2.2. Idiopathic pulmonary fibrosisIdiopathic pulmonary fibrosis

    33.. Interstitial pneumonitisInterstitial pneumonitis

    44.. TuberculosisTuberculosis

    55.. Pnuemonectomy (loss of lung)Pnuemonectomy (loss of lung)

    66.. PneumoniaPneumonia

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    66/84

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    67/84

    PFT IPFT I 6767

    C.C. Neuromuscular Restrictive LungNeuromuscular Restrictive LungDisordersDisorders

    1.1. Generalized WeaknessGeneralized Weakness malnutritionmalnutrition

    2.2. Paralysis of the diaphragmParalysis of the diaphragm

    3.3. Myasthenia GravisMyasthenia Gravis

    4.4. Muscular DystrophyMuscular Dystrophy

    5.5. PoliomyelitisPoliomyelitis

    6.6. Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    68/84

    PFT IPFT I 6868

    Full expantion of the lungFull expantion of the lungis limited and thereforeis limited and thereforethethe FVCFVC is reducedis reduced

    FEVFEV11 may be reducedmay be reducedbecause the stiffness ofbecause the stiffness of

    fibrotic lungs increasesfibrotic lungs increasesthe expiratory pressurethe expiratory pressure

    FEVFEV11/FVC/FVC will be Normalwill be Normalor Increasedor Increased

    *if you suspect restrictive*if you suspect restrictivepattern you must checkpattern you must checkTLCTLC

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    69/84

    PFT IPFT I 6969

    Flow volume loop inFlow volume loop in

    Restrictive lung diseaseRestrictive lung disease

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    70/84

    PFT IPFT I 7070

    Flow volume loop inFlow volume loop inRestrictive lung diseaseRestrictive lung disease :: Full lung expantion isFull lung expantion is

    prevented by fibrotic tissue inprevented by fibrotic tissue inthe lung parenchyma and thethe lung parenchyma and theFVCFVC is reduced .is reduced .

    Elastic recoil may increased byElastic recoil may increased byfibrotic tissue lead to increasefibrotic tissue lead to increasethe airflowthe airflow

    BothBoth FEV1FEV1 andand FVCFVC may bemay bereduced because the lungs arereduced because the lungs aresmall and stiff ,but the peaksmall and stiff ,but the peakexpiratory flow may beexpiratory flow may be

    preserved or even higher thanpreserved or even higher thanpredicted leads to tall,narrowpredicted leads to tall,narrowand steep flow volume loop inand steep flow volume loop inexpiratory phase.expiratory phase.

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    71/84

    PFT IPFT I 7171

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    72/84

    PFT IPFT I 7272

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    73/84

    PFT IPFT I 7373

    ExampleExample

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    74/84

    PFT IPFT I 7474

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    75/84

    PFT IPFT I 7575

    Mild restrictive defect suggested by reduced in FVCMild restrictive defect suggested by reduced in FVCwith normal to high FEV1/FVCwith normal to high FEV1/FVC

    Need lung volume and diffusion capacity to assess ifNeed lung volume and diffusion capacity to assess ifit is intrinsic or extrinsic typeit is intrinsic or extrinsic type

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    76/84

    PFT IPFT I 7676

    Obstructive & restrictive defectsObstructive & restrictive defects

    ParameterParameter ObstructionObstruction RestrictionRestrictionFEVFEV11 ReducedReduced ReducedReduced

    FVCFVC NormalNormal ReducedReduced

    FEVFEV11/FVC/FVC ReducedReduced NormalNormal

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    77/84

    PFT IPFT I 7777

    Acceptability andReproducibilityAcceptability andReproducibility

    CriteriaCriteria

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    78/84

    PFT IPFT I 7878

    Acceptability CriteriaAcceptability Criteriafree from artifacts:free from artifacts: Cough or glottis closure during the first second ofCough or glottis closure during the first second of

    exhalationexhalation Eary termination or cutoffEary termination or cutoff Variable effortVariable effort

    LeakLeak Obstructed mouthpieceObstructed mouthpiece Have good startsHave good starts Have a satisfactory exhalationHave a satisfactory exhalation 6 s of exhalation6 s of exhalation

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    79/84

    PFT IPFT I 7979

    R

    eproducibility CriteriaR

    eproducibility CriteriaAfter 3 acceptable spirograms been obtainedAfter 3 acceptable spirograms been obtained Are the two largest FVC within 0.2 L of each other?Are the two largest FVC within 0.2 L of each other?

    Are the two largest FEV1 within 0.2 L of each other?Are the two largest FEV1 within 0.2 L of each other?

    If both of these criteria are met, the test session mayIf both of these criteria are met, the test session maybe concluded.be concluded.

    If both of these criteria are not met, continue testingIf both of these criteria are not met, continue testing

    until Both of the criteria are met with analysis ofuntil Both of the criteria are met with analysis ofadditional acceptable spirograms; OR a total of eightadditional acceptable spirograms; OR a total of eighttests have been performedtests have been performed

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    80/84

    PFT IPFT I 8080

    Acceptability of the testAcceptability of the test

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    81/84

    PFT IPFT I 8181

    Early Glottic Closure

    Normal

    Poor EffortCough

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    82/84

    PFT IPFT I 8282

    ExampleExample

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    83/84

    PFT IPFT I 8383

    1.What is the defect?1.What is the defect?

  • 8/6/2019 Pulmonary Function Test Part 1 PptDr Mona Allangawi

    84/84

    Mild obstructive defect with good response toMild obstructive defect with good response tobronchodilatorbronchodilator

    DiagnosisDiagnosisB.AsthmaB.Asthma